|
1
|
Brundage MD, Davies D and Mackillop WJ:
Prognostic factors in non-small cell lung cancer: A decade of
progress. Chest. 122:1037–1057. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rudin CM, Brambilla E, Faivre-Finn C and
Sage J: Small-cell lung cancer. Nat Rev Dis Primers.
7(3)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fukui T, Yatabe Y, Kobayashi Y, Tomizawa
K, Ito S, Hatooka S, Matsuo K and Mitsudomi T: Clinicoradiologic
characteristics of patients with lung adenocarcinoma harboring
EML4-ALK fusion oncogene. Lung Cancer. 77:319–325. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Aydemirli MD, van Eendenburg JDH, van
Wezel T, Oosting J, Corver WE, Kapiteijn E and Morreau H: Targeting
EML4-ALK gene fusion variant 3 in thyroid cancer. Endocr Relat
Cancer. 28:377–389. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kawamoto H, Kaneko Y, Ryu K and Kuwano K:
Thyroid metastasis from lung adenocarcinoma with EML4-ALK
rearrangement. BMJ Case Rep. 2016(bcr2016217541)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
McCusker MG, Russo A, Scilla KA, Mehra R
and Rolfo C: How I treat ALK-positive non-small cell lung cancer.
ESMO Open. 4 (Suppl 2)(e000524)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jassem J: Alectinib in
crizotinib-resistant, ALK-positive NSCLC. Lancet Oncol. 17:134–135.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Song Z, Wang M and Zhang A: Alectinib: A
novel second generation anaplastic lymphoma kinase (ALK) inhibitor
for overcoming clinically-acquired resistance. Acta Pharm Sin B.
5:34–37. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Can AS and Köksal G: Thyroid metastasis
from small cell lung carcinoma: A case report and review of the
literature. J Med Case Rep. 9(231)2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tang Q and Wang Z: Metastases to the
thyroid gland: What can we do? Cancers (Basel).
14(3017)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
LaPar DJ, Bhamidipati CM, Lau CL, Jones DR
and Kozower BD: The Society of Thoracic Surgeons General Thoracic
Surgery Database: Establishing generalizability to national lung
cancer resection outcomes. Ann Thorac Surg. 94:216–221; discussion
221. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hegerova L, Griebeler ML, Reynolds JP,
Henry MR and Gharib H: Metastasis to the thyroid gland: Report of a
large series from the Mayo Clinic. Am J Clin Oncol. 38:338–342.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Antonoff MB and D'Cunha J: Non-small cell
lung cancer: The era of targeted therapy. Lung Cancer (Auckl).
3:31–41. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Dong J, Li B, Lin D, Zhou Q and Huang D:
Advances in targeted therapy and immunotherapy for non-small cell
lung cancer based on accurate molecular typing. Front Pharmacol.
10(230)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chia PL, Mitchell P, Dobrovic A and John
T: Prevalence and natural history of ALK positive non-small-cell
lung cancer and the clinical impact of targeted therapy with ALK
inhibitors. Clin Epidemiol. 6:423–432. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Camidge DR, Kono SA, Flacco A, Tan AC,
Doebele RC, Zhou Q, Crino L, Franklin WA and Varella-Garcia M:
Optimizing the detection of lung cancer patients harboring
anaplastic lymphoma kinase (ALK) gene rearrangements potentially
suitable for ALK inhibitor treatment. Clin Cancer Res.
16:5581–5590. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sgambato A, Casaluce F, Maione P and
Gridelli C: Targeted therapies in non-small cell lung cancer: A
focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer
Ther. 18:71–80. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Desai A and Lovly CM: Strategies to
overcome resistance to ALK inhibitors in non-small cell lung
cancer: A narrative review. Transl Lung Cancer Res. 12:615–628.
2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hizal M, Bilgin B, Paksoy N, Atcı MM,
Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö,
et al: The percentage of ALK-positive cells and the efficacy of
first-line alectinib in advanced non-small cell lung cancer: Is it
a novel factor for stratification? (Turkish Oncology Group Study).
J Cancer Res Clin Oncol. 149:4141–4148. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Esagian SM, Grigoriadou GI, Nikas IP,
Boikou V, Sadow PM, Won JK and Economopoulos KP: Comparison of
liquid-based to tissue-based biopsy analysis by targeted next
generation sequencing in advanced non-small cell lung cancer: A
comprehensive systematic review. J Cancer Res Clin Oncol.
146:2051–2066. 2020.PubMed/NCBI View Article : Google Scholar
|
